Compare IIIN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | LXRX |
|---|---|---|
| Founded | 1953 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.9M | 541.5M |
| IPO Year | N/A | 2000 |
| Metric | IIIN | LXRX |
|---|---|---|
| Price | $33.13 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 114.8K | ★ 1.5M |
| Earning Date | 01-15-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 112.14 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $647,706,000.00 | $70,864,000.00 |
| Revenue This Year | $14.97 | $56.61 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $15.82 | ★ N/A |
| Revenue Growth | 22.39 | ★ 1255.21 |
| 52 Week Low | $22.49 | $0.28 |
| 52 Week High | $41.64 | $1.66 |
| Indicator | IIIN | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 46.47 |
| Support Level | $31.34 | $1.29 |
| Resistance Level | $32.24 | $1.48 |
| Average True Range (ATR) | 0.69 | 0.07 |
| MACD | 0.39 | -0.01 |
| Stochastic Oscillator | 92.04 | 28.96 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.